Differences in Clinical and Imaging Features between Asymptomatic and Symptomatic COVID-19 Patients

Table 3

Imaging of asymptomatic carriers and COVID-19 patients in the early stage [n (%)].

CT features	Early stage
	Asymptomatic (n = 19)	COVID-19 (n = 15)
Prevalent lesion distribution within lobes
Peripheral area	14 (73.68)	4 (26.67)	7.44	0.006
Central area	1 (5.3)	1 (6.67)	0.03	1.000
Both peripheral and central areas	4 (21.05)	10 (66.67)	7.20	0.007
Lesion density and interior features
Ground glass opacity	6 (31.58)	5 (33.33)	0.01	1.000
Consolidation	1 (5.3)	2 (13.33)	0.68	0.57
Both ground-glass opacity and consolidation	12 (63.16)	8 (53.33)	0.33	0.56
Intralobular septal thickening	11 (57.89)	7 (46.66)	0.42	0.52
Interlobular septal thickening	3 (15.79)	3 (20.0)	0.10	1.00
Other features			0.71	1.00
Pleural effusion	1 (5.3)	0
Enlarged mediastinal lymph nodes	0	0

Note. Asymptomatic, those who remained asymptomatic; COVID-19, symptomatic COVID-19 patients; the fisher exact test was used.